What Travelers to East Africa Should Know About the Ebola Outbreak

"Like other forms of Ebola, Bundibugyo virus disease can cause fever, fatigue, vomiting, diarrhea, and, in severe cases, internal and external bleeding. It spreads through direct contact with bodily fluids from infected people or contaminated materials, rather than through the air like Covid-19 or flu."

"According to the World Health Organization, previous Bundibugyo outbreaks have generally recorded lower fatality rates than the better-known Zaire strain, although the disease is still considered highly dangerous and capable of spreading rapidly in areas with limited healthcare infrastructure."

"The key difference is that there are currently no approved vaccines or targeted treatments specifically available for the Bundibugyo strain. Most recent Ebola responses, including vaccines deployed during outbreaks in West Africa and the Democratic Republic of the Congo, were developed for the Zaire strain of Ebola virus, which has historically caused the deadliest outbreaks."

"Health authorities say those treatments have not been formally approved for Bundibugyo virus disease. The strain is considered somewhat less lethal than Zaire Ebola on average, with historical fatality rates estimated at roughly 25% to 50%, compared with up to 90% in some past Zaire outbreaks. But experts are warning that mortality rates vary widely depending on how quickly cases are detected, how effectively contacts are traced, and the quality of local healthcare responses."

Bundibugyo virus disease causes fever, fatigue, vomiting, and diarrhea, and can lead to internal and external bleeding in severe cases. Transmission occurs through direct contact with bodily fluids from infected people or contaminated materials, not through the air. Previous outbreaks have generally shown lower fatality rates than Zaire Ebola, but the disease remains highly dangerous and can spread rapidly where healthcare resources are limited. No approved vaccines or targeted treatments specifically exist for the Bundibugyo strain, and existing Ebola countermeasures developed for the Zaire strain have not been formally approved for Bundibugyo. Mortality varies based on early detection, contact tracing effectiveness, and local healthcare quality. People typically become infectious once symptoms begin, making casual contact lower risk than direct physical contact with a sick person.

Read at Conde Nast Traveler